Details of the Drug

General Information of Drug (ID: DMHYLQ2)

Drug Name

Lithium chloride

Synonyms

LITHIUM CHLORIDE; 7447-41-8; Lithiumchloride; Lithium chloride (LiCl); LiCl; chlorure de lithium; Chlorku litu; chlorolithium; Lithiumchlorid; Chlorku litu [Polish]; Luthium chloride; Chlorure de lithium [French]; CCRIS 5924; UNII-G4962QA067; HSDB 4281; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; CHEMBL69710; CHEBI:48607; NSC327172; MFCD00011078; G4962QA067; Lithium chloride, 99%, extra pure; ClLi; Lithium chloride, 99+%, ACS reagent; Lithium chloride, 99%, for molecular biology; Lithium chloride, 99%, for analysis, anhyd

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

42.4

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

Chemical Identifiers

Formula: ClLi
IUPAC Name: lithium;chloride
Canonical SMILES: [Li+].[Cl-]
InChI: InChI=1S/ClH.Li/h1H;/q;+1/p-1
InChIKey: KWGKDLIKAYFUFQ-UHFFFAOYSA-M

Cross-matching ID

PubChem CID: 433294
ChEBI ID: CHEBI:48607
CAS Number: 7447-41-8
DrugBank ID: DB16607
TTD ID: D07WXT

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycogen synthase kinase-3 alpha (GSK-3A)	TTRZQE3	GSK3A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)	OTOA8WU2	PDE4B_HUMAN	Gene/Protein Processing	[2]
4-aminobutyrate aminotransferase, mitochondrial (ABAT)	OTXAGR7J	GABT_HUMAN	Gene/Protein Processing	[3]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Gene/Protein Processing	[2]
Abl interactor 2 (ABI2)	OT8GIIS5	ABI2_HUMAN	Gene/Protein Processing	[2]
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Protein Interaction/Cellular Processes	[4]
Acylamino-acid-releasing enzyme (APEH)	OTX258QE	ACPH_HUMAN	Gene/Protein Processing	[2]
Adenomatous polyposis coli protein 2 (APC2)	OTRH91CX	APCL_HUMAN	Gene/Protein Processing	[2]
Adhesion G protein-coupled receptor B3 (ADGRB3)	OT1EWGRW	AGRB3_HUMAN	Gene/Protein Processing	[3]
Adhesion G protein-coupled receptor E5 (ADGRE5)	OTTSB84Q	AGRE5_HUMAN	Gene/Protein Processing	[2]
ADP-ribosylation factor 6 (ARF6)	OTVV7KJO	ARF6_HUMAN	Gene/Protein Processing	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6.
2	Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
3	Early gene response in lithium chloride induced apoptosis. Apoptosis. 2005 Jan;10(1):75-90. doi: 10.1007/s10495-005-6063-x.
4	Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3beta. Chem Biol Interact. 2013 Mar 25;203(1):309-13.